ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 33 citations in OpenAlex.
- Sex-Specific Associations ofThe world journal of men's health · 2026Article
- Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.Journal of gastroenterology and hepatology · 2026Article
- Common crosstalk genes and molecular mechanisms in Helicobacter pylori infection and colorectal cancer.Discover oncology · 2026Article
- The microbiota-metabolite-immune axis in colorectal cancer: mechanistic insights and emerging clinical applications.Frontiers in immunology · 2026Review
- HELICOBACTER PYLORI BEYOND THE STOMACH: WHEN THE STORY CHANGES.Arquivos de gastroenterologia · 2026Review
- Screening, Characterization, and Mode of Action of Three Lactic Acid Bacteria Against Helicobacter pylori.Probiotics and antimicrobial proteins · 2026Article
- Global and regional burden of colorectal cancer potentially related to Helicobacter pylori exposure: a risk attribution modelling study.eGastroenterology · 2026Article
- Overexpression of lncRNA ATP11A-AS1 in Colorectal Cancer and Its Association WithInternational journal of genomics · 2026Article
- [Helicobacter pylori].Innere Medizin (Heidelberg, Germany) · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- Helicobacter pylori, peptic ulcer disease, and colorectal cancer: a prospective study with genome-wide interaction analysis and Mendelian randomization.Infectious agents and cancer · 2025Article
- Nonlinear Relationship Between Myeloperoxidase Levels andJournal of clinical medicine · 2025Article
- Article
- Bacteria and Carcinogenesis and the Management of Cancer: A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
- Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.International journal of molecular sciences · 2025Review
- Detecting PI3K and TP53 Pathway Disruptions in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients.Cancer medicine · 2025Article
- Effect ofImmunotherapy · 2025Review
- Beyond the stomach: the association betweenFrontiers in cellular and infection microbiology · 2025Review
- Follow your "gut"-calling for colonoscopy in patients with upper gastrointestinal adenomas: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2025Article
- Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship toFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
purposePATIENTS: US Veterans who completed H. pylori testing between 1999 and 2018.
methodsWe conducted a retrospective cohort analysis among adults within the Veterans Health Administration who completed testing for H. pylori. The primary exposures were (1) H. pylori test result (positive/negative) and (2) H. pylori treatment (untreated/treated) among H. pylori-positive individuals. The primary outcomes were CRC incidence and mortality. Follow-up started at the first H. pylori testing and continued until the earliest of incident or fatal CRC, non-CRC death, or December 31, 2019.
resultsAmong 812,736 individuals tested for H. pylori, 205,178 (25.2%) tested positive. Being H. pylori-positive versus H. pylori-negative was associated with higher CRC incidence and mortality. H. pylori treatment versus no treatment was associated with lower CRC incidence and mortality (absolute risk reduction 0.23%-0.35%) through 15-year follow-up. Being H. pylori-positive versus H. pylori-negative was associated with an 18% (adjusted hazard ratio [adjusted HR], 1.18 [95% CI, 1.12 to 1.24]) and 12% (adjusted HR, 1.12 [95% CI, 1.03 to 1.21]) higher incident and fatal CRC risk, respectively. Individuals with untreated versus treated H. pylori infection had 23% (adjusted HR, 1.23 [95% CI, 1.13 to 1.34]) and 40% (adjusted HR, 1.40 [95% CI, 1.24 to 1.58]) higher incident and fatal CRC risk, respectively. The results were more pronounced in the analysis restricted to individuals with nonserologic testing.
conclusionH. pylori positivity may be associated with small but statistically significant higher CRC incidence and mortality; untreated individuals, especially those with confirmed active infection, appear to be most at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.